Combined treatment of parkinsonism with L-dopa and amantadine.
D000368:Aged; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002819:Chorea / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009129:Muscle Tonus; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy; D010919:Placebos; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D010919:Placebos; D004295:Dihydroxyphenylalanine; D000547:Amantadine